GIL 2026 | 沙利文授予普洛药业2026年沙利文全球CDMO年度公司奖

Founded in 1989, Pulo Pharmaceutical is a comprehensive pharmaceutical company focused on innovative drug research, development, and production services (CDMO), active pharmaceutical ingredients, intermediates, and drug business. Operating under the development strategy of "refining raw materials, strengthening CDMO, improving drugs, and expanding beauty medicine," the company continuously advances its operations toward high-tech barriers, high value added, platformization, and globalization. From 2020 to 2025, the CDMO business of Pulo Pharmaceutical experienced a compound annual growth rate of 16%, with a gross margin of over 41%. These three strategic pillars have driven the high-quality growth of Pulo Pharmaceutical’s CDMO business.

随着创新药分子结构和生产工艺日益复杂，全球药企对CDMO合作伙伴的需求正由基础产能供给转向复杂工艺开发与产业化能力。

Pulo Pharmaceutical focuses on strategic investmentsFluid Chemistry、寡核苷酸、多肽、ADC连接子（Linker）及小分子毒素（Payload）等高技术壁垒平台。其中，流体化学平台可用于高危反应、Chiral synthesisComplex processes, enhancing production safety, reaction efficiency, and batch stability. Through the aforementioned platform, the company can participate from the early process design and route development stages, helping clients overcome "challenge points" in the synthesis, scale-up, impurity control, and stable production of complex molecules. Prolu Pharmaceuticals is transitioning from traditional methodsAPIProducers are transforming into technical partners with the capability to develop "the most challenging drugs" in order to leverage their differentiated technical capabilities for early innovation and accelerate industrialization.

Under the context of the global pharmaceutical supply chain restructuring, compliance and large-scale delivery capabilities have become important security measures for multinational pharmaceutical companies when selecting CDMO partners. Prolu Pharmaceutical has developed integrated service capabilities covering intermediates, APIs, and formulations, which can support the smooth transition of projects from pre-clinical and clinical development to validation and commercial production, reducing technical transfer and supply chain integration issues, and lowering project development and delivery risks. The company combines large-scale capacity with multi-functional flexible production, high-activity compounds, fluid chemistry, andContinuousization、自动化、数字化和智能化制造能力相结合，为不同阶段和规模的项目提供灵活支持。同时，公司建立了覆盖研发、技术转移、生产、质量控制及商业化供应的全球合规体系，并保持FDA检查"零缺陷"记录，为客户提供高质量、高效率、可追溯的规模化交付，以供应确定性支持全球药企应对供应链风险。

ProLuo Pharmaceutical has established a “Iron Triangle” R&D network in Boston, Shanghai, and Hangzhou, connecting global innovation sources, technology development platforms, and large-scale production bases. The overseas team is close to global biopharmaceutical innovation clusters and multinational pharmaceutical clients, while domestic R&D and manufacturing resources provide support in process development, technology transfer, and commercial production. The company has served 713 global clients across major pharmaceutical markets in China, Europe, North America, and Japan; overseas business revenue accounts for 44.32% of the company’s total revenue. By leveraging global business, R&D, and production resources, the company can respond seamlessly to customer needs across time zones, offer customized solutions based on regional regulatory requirements and project stages, stay connected to global innovation sources, and provide continuous support from early R&D to commercial supply.